The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: To investigate the association of adipocytokines and other inflammatory markers with development of GDM. Methods: Serum adipocytokines and inflammatory markers were studied at 12 to 15 weeks gestation using biobanked control samples from a randomised trial. Study participants were identified as high risk for GDM using a validated clinical risk prediction tool. Markers were tested using commercial ELISA kits for high molecular weight (HMW) adiponectin, interleukin‐6 (IL‐6), plasminogen activator inhibitor‐1, visfatin, omentin‐1, sex‐hormone binding globulin, monocyte chemoattractant protein, and asymmetrical dimethylarginine. The association between each biomarker and development of GDM at 24 to 28 weeks was evaluated using multivariable logistic regression analysis adjusted for maternal factors. Results: There were no differences in age, parity, country of birth, smoking, body mass index, or family history of diabetes in women with normal glucose tolerance (n = 78) and women who developed GDM (n = 25). Women with GDM were more likely to have a past history of GDM (P = 0.004). HMW adiponectin (odds ratio OR 0.37 [95% confidence interval 0.19–0.74]), omentin‐1 (0.97 [0.94–0.99]), and IL‐6 (1.87[1.03–3.37]) were associated with development of GDM, after adjustment for maternal age, body mass index, and past history of GDM. The other markers were not associated with GDM development. Conclusions: Decreased high molecular weight adiponectin and omentin‐1 and increased IL‐6 may enhance sensitivity of early risk prediction tools for women at high risk of GDM. This may allow early identification and opportunities for prevention of GDM and adverse outcomes. Further research is required in large validation studies to confirm these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increasing Prevalence of Gestational Diabetes Mellitus
Ferrara, A. (2007) · Diabetes Care · doi:10.2337/dc07-s206 · Cited by 1,171
Williams, M. A., Qiu, C., Muy-Rivera, M., Vadachkoria, S., Song, T., & Luthy, D. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031201 · Cited by 220
Screening for biomarkers predictive of gestational diabetes mellitus
Georgiou, H. M., Lappas, M., Georgiou, G. M., Marita, A., Bryant, V. J., Hiscock, R., Permezel, M., Khalil, Z., & Rice, G. E. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0037-8 · Cited by 151
Cited by
Lorenzo-Almorós, A., Hang, T., Peiró, C., Soriano-Guillén, L., Egido, J., Tuñón, J., & Lorenzo, Ó. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0935-9 · Cited by 202
New Insights into Adipokines in Gestational Diabetes Mellitus
Valencia-Ortega, J., González-Reynoso, R., Ramos-Martínez, E. G., Ferreira-Hermosillo, A., Peña-Cano, M. I., Morales-Ávila, E., & Saucedo, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116279 · Cited by 39
“(2017) [23] Cohort 103 (25 GDM and 78 controls) Weeks 12–15 ↔ +BMI at the time of blood sampling +GDM risk”
BackgroundInfluentialBiochemical and Molecular Biomarkers: Unraveling Their Role in Gestational Diabetes Mellitus
Karami, M., Mousavi, S. H., Rafiee, M., Heidari, R., & Shahrokhi, S. Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00980-8 · Cited by 33
Impact of Gestational Diabetes Mellitus on Fetal Growth and Nutritional Status in Newborns
Karcz, K., & Królak-Olejnik, B. (2024) · Nutrients · doi:10.3390/nu16234093 · Cited by 25
“Conversely, low omentin-1 levels in the first trimester of pregnancy were associated with a fourfold increased risk of developing gestational diabetes mellitus during pregnancy [44].”
Metadata
- Authors
- Abell, S. K., Shorakae, S., Harrison, C. L., Hiam, D., Moreno‐Asso, A., Stepto, N. K., De Courten, B., & Teede, H. J.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2017-09-15
- Volume
- 33
- Issue
- 8
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2747055612
- Cited by
- 46
- References
- 3
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.